AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 86 filers reported holding AVADEL PHARMACEUTICALS PLC in Q1 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $317,000 | -43.4% | 39,273 | -31.3% | 0.04% | -29.8% |
| Q3 2021 | $560,000 | +57.3% | 57,148 | +8.0% | 0.06% | +42.5% |
| Q2 2021 | $356,000 | +215.0% | 52,933 | +136.4% | 0.04% | +110.5% |
| Q3 2020 | $113,000 | -4.2% | 22,390 | +53.3% | 0.02% | -71.2% |
| Q2 2020 | $118,000 | -42.4% | 14,610 | -68.6% | 0.07% | +500.0% |
| Q3 2018 | $205,000 | -85.8% | 46,597 | -80.2% | 0.01% | -84.7% |
| Q2 2018 | $1,442,000 | -37.4% | 235,217 | -25.6% | 0.07% | -41.0% |
| Q1 2018 | $2,303,000 | +11.9% | 315,960 | +25.9% | 0.12% | -2.4% |
| Q4 2017 | $2,058,000 | +34.8% | 251,033 | +72.6% | 0.12% | +20.2% |
| Q3 2017 | $1,527,000 | -30.8% | 145,423 | -27.4% | 0.10% | -27.8% |
| Q2 2017 | $2,208,000 | +25.2% | 200,213 | +9.9% | 0.14% | +51.6% |
| Q1 2017 | $1,763,000 | – | 182,157 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,498,838 | $22,889,355 | 11.72% |
| Knoll Capital Management, LLC | 500,000 | $4,580,000 | 7.06% |
| GENDELL JEFFREY L | 5,301,914 | $48,565,532 | 4.55% |
| COWEN AND COMPANY, LLC | 3,732,778 | $34,192,246 | 4.02% |
| Tri Locum Partners LP | 1,327,097 | $12,156,209 | 3.70% |
| Samsara BioCapital, LLC | 1,409,409 | $12,910,186 | 2.67% |
| Altium Capital Management LP | 500,000 | $4,580,000 | 2.54% |
| Vivo Capital, LLC | 3,761,438 | $34,454,772 | 2.39% |
| RTW INVESTMENTS, LP | 5,741,939 | $52,596,161 | 1.10% |
| Knott David M Jr | 291,113 | $2,667 | 1.05% |